Table 3 Comparison of clinical characteristics according to APOE genotype in elderly patients with schizophrenia
Item | APOE ε2(n = 40) | APOE ε3(n = 205) | APOE ε4(n = 49) | x 2 /F | P-value | |
|---|---|---|---|---|---|---|
Men (%) | 23 (57.5%) | 109 (53.2%) | 26 (53.1%) | 0.263 | 0.877 | |
Age (years) | 67.65 ± 7.17 | 67.10 ± 6.54 | 68.00 ± 6.58 | 0.422 | 0.656 | |
Overweight status (%) | 18 (45.0%) | 98 (47.8%) | 21 (42.9%) | 0.437 | 0.804 | |
History of disease | Diabetes (%) | 11 (27.5%) | 52 (25.4%) | 12 (24.5%) | 0.112 | 0.945 |
High blood pressure (%) | 11 (27.5%) | 78 (38.0%) | 19 (38.8%) | 1.708 | 0.426 | |
Drug use* | Atypical antipsychotic use (%) | 36 (90.0%) | 179 (87.3%) | 45 (91.8%) | 0.751# | |
Chlorpromazine equivalent dose (mg) | 322.88 ± 320.06 | 318.52 ± 254.79 | 361.98 ± 371.20 | 0.459 | 0.490 | |
Lipid-lowering mediation use (%) | 1 (2.5%) | 6 (2.9%) | 7 (14.3%) | 0.006# | ||
Glucose-lowering medication use (%) | 9 (22.5%) | 43 (21.0%) | 12 (24.5%) | 0.296 | 0.863 | |
Serum biochemical indices& | Triglycerides (mmol/L) | 1.35 ± 0.81 | 1.38 ± 0.84 | 1.43 ± 0.80 | 0.062 | 0.940 |
Cholesterol (mmol/L) | 4.38 ± 0.91 | 4.74 ± 0.91 | 4.94 ± 1.47 | 2.994 | 0.052 | |
High-density lipoprotein (mmol/L) | 1.36 ± 0.35 | 1.29 ± 0.41 | 1.25 ± 0.45 | 0.812 | 0.445 | |
Low-density lipoprotein (mmol/L) | 2.34 ± 0.63 | 2.83 ± 0.75 | 2.85 ± 0.98 | 7.038 | 0.001 | |
Plasma glucose (mmol/L) | 5.58 ± 1.40 | 5.50 ± 1.49 | 5.27 ± 0.89 | 1.198 | 0.303 |